NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today announced that the company has agreed on a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for a pivotal Phase II clinical trial to evaluate Tamibarotene, its drug candidate for the treatment of relapsed or refractory acute promyelocytic leukemia (APL). APL is a subtype of acute myeloid leukemia (AML).
